We use cookies for a better user experience. Read our Privacy Policy

I Agree

Primary Immunodeficiency Market

Primary Immunodeficiency Market (Type: Antibody Deficiency, Cellular Deficiency, and Innate Immune; and End User: Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell and Gene Therapy, and Others [Vaccines, Nutritional Supplements, and Others]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2028

Research and Development to Accelerate New Drug Development and Gene-sequencing

Advancements in technology and medical science have played a key role in the development of new treatments and therapies for an array of disorders and diseases. Conventionally, primary immunodeficiencies have been predominantly characterized as per the immunologic phenotype. Research and development activities within the primary immunodeficiency market are largely focused on the discovery of human genes that could cause primary immunodeficiency. More recently, four distinct genetic defects that could potentially lead to primary immunodeficiency diseases and acute congenital neutropenia continue to drive research in the primary immunodeficiency market.

Some of the key areas within the primary immunodeficiency market that are currently being investigated include the role of follicular T cells in the development of antibody responses, the link between impaired B-cell maturation and inflammatory conditions, inflammatory and autoimmune manifestations, and recently discovered gene defects. Moreover, several researchers are exploring the overall efficacy of the lentiviral vector-mediated gene therapies in patients that are suffering from adenosine deaminize-deficient severe combined immunodeficiency (SCID). Over the past decade, the management of primary immunodeficiency has advanced at a rapid pace due to a surge in investments and focus on research. Strides taken by sequencing, gene-editing tools, and the development of new drugs are expected to boost the prospects of the market for primary immunodeficiency during the forecast period. At the back of these factors, the global primary immunodeficiency market is expected to attain reach a value of ~US$ 9.9 Bn by the end of 2028.

To know the scope of our report Get a Sample on Primary Immunodeficiency Market

Advancements in Genetic Management and Next-generation Sequencing Technologies to Aid Market Growth

One of the most common symptomatic primary immunodeficiency disorders that continues to attract investments and research include the common variable immunodeficiency disorder. The onset of genome sequencing and soaring interest in genome-wide association studies have played a key role in enhancing and understanding the overall genetics of common variable primary immunodeficiency. Research has also opened up new frontiers as far as understanding the pathogenesis of common variable primary immunodeficiency. In recent times, the adoption of DNA sequencing, RNA sequencing, epigenetic, and proteomic profiles is on the rise to assess common variable primary immunodeficiency that is linked with disease pathways and other therapeutic targets. Scientists and researchers are increasingly focusing on understanding the genetics of primary immunodeficiency.

Get a glimpse of the in-depth analysis through our Report Brochure

The prevalence of primary immunodeficiency around the world is on the rise due to which, the demand for novel treatments and therapies has witnessed considerable growth. Significant progress in sequencing technologies is triggered by the discovery of a range of monogenic forms of common variable primary immunodeficiency. Over the past decade, due to advancements in technology and research, participants of the primary immunodeficiency market are swaying toward the use of omics-based technologies and integrating next-generation platforms in the common variable primary immunodeficiency space.

Advancements in Molecular Techniques Open up New Treatment Alternatives for Primary Immunodeficiency Disorders

Over the past few decades, inborn errors of immunity (IEIs) have witnessed exponential growth. In addition, over 400 glaring defects have been listed in the recently amended International Union of Immunological Societies (IUIS). In the past few years, due to considerable information pertaining to new genes and diseases, the primary immunodeficiency market is set to witness notable development and likely to emphasize on the concept of “inborn errors of immunity” as a collective group of various phenotypes such as infection, autoimmunity, autoinflammation, malignancy, allergy, etc. Developments in molecular studies have streamlined the detection of an array of potential targets for certain therapeutic interventions. Targeted therapies constitute small molecules and monoclonal antibodies, including cytokine inhibitors and cytokines. Some of the most popular and extensively used targeted therapies include rituximab— a therapy deployed to cater to issues related to autoimmune and lymph proliferative manifestations. Apart from noteworthy developments in molecular studies, gene therapies have also gained a great amount of popularity over the past three decades. The adoption of gene therapy in the primary immunodeficiency market has increased at a consistent pace since the 1990s, particularly to address X-SCID and ADA-SCID.

Although developments in molecular studies are expected to augment the market for primary immunodeficiency, companies in the current market landscape are expected to overcome a few major roadblocks, including increasing the availability of different diagnostic tools and treatments to patients across the world and offering customized treatments cost-effectively.

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

The global primary immunodeficiency market is expected to grow at a healthy CAGR of ~6% during the forecast period. The market growth can be primarily attributed to a host of factors, including advancements in molecular studies, rapid strides taken by next-generation sequencing technologies, DNA sequencing, and RNA sequencing. Research and development activities will continue to play a key role in boosting the prospects of the new primary immunodeficiency treatment and therapies. Companies operating in the current market landscape should ideally focus on the development of tailor-made primary immunodeficiency therapies to gain an edge.

Primary Immunodeficiency Market: Overview

  • According to Transparency Market Research’s latest research report on the global primary immunodeficiency market for the historical period (2017–2018) and the forecast period (2020–2028), high prevalence of hypertension is anticipated to drive the global primary immunodeficiency market in the near future
  • According to the report, the global primary immunodeficiency market was valued at US$ 5.7 Bn in 2019 and is projected to expand at a CAGR of ~6% from 2020 to 2028​

Government Approval for New Therapies for PIDD Treatment: A Key Driver

  • On April 1, 2019, the U.S. Food and Drug Administration (FDA) approved ADMA Biologics’ Asceniv to treat primary humoral immunodeficiency disease (PIDD or PI) in adults and adolescents
  • On Sep 14, 2016, the U.S. Food and Drug Administration (FDA) granted Shire approval for CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in adult and pediatric patients two years of age and older
  • On October 5, 2018, Leadiant Biosciences, Inc. announced that the Food and Drug Administration (FDA) granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy (ERT) for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
  • On September 12, 2014, Baxter International Inc. (2.20%) and Halozyme Therapeutics, Inc. (0.73%) announced that the U.S. Food and Drug Administration (FDA) approved Baxter’s subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA Immune Globulin Infusion 10% (Human) with recombinant human Hyaluronidase
  • All the above mentioned products offer cost-effective treatment for PIDD and deliver full therapeutic dose of immune globulin to patients
  • Therefore, such approvals increase the demand for primary immunodeficiency diseases treatment, leading to market growth

Gradual Increase in Incidence of Primary Immunodeficiency Diseases Globally

  • Gradual rise in incidence rate of primary immunodeficiency diseases such as common variable immune deficiency, Ataxia Telangiectasia, and complement deficiencies drives the primary immunodeficiency disorder market
  • Early diagnosis of PID is critical for preventing significant disease-associated morbidity and even mortality. The national surveys of PID conducted by the Immune Deficiency Foundation in the U.S. found that approximately 60% of patients with these disorders were not diagnosed until adulthood despite the fact that many reported serious or chronic health conditions prior to diagnosis, such as sinusitis, bronchitis, and pneumonia.
  • According to an article in the Allergy, Asthma & Clinical Immunology, with the exception of IGA deficiency (prevalence = 1 in 300–500), PIDs are more frequent than the estimated prevalence of 1 in 1200 live births
  • Advanced testing for detecting the presence or function of cellular proteins is carried out to confirm the diagnosis of PID. Moreover, testing for genetic causes is an important component of diagnosis. These are expensive and thus, ignorance can also lead to increase in prevalence and spread of the disease.
  • According to an article in the Journal of Clinical Immunology, the population prevalence of diagnosed PID in the U.S. is 1 in 1,200 people. This translates into a population rate for diagnosed PID of 0.0863%. When applied to the U.S. population of 297,386,000 persons, this gives an estimate of approximately 250,000 persons with diagnosed PID in the U.S.
  • Therefore, gradual increase in incidence rate would, in turn, drive the demand for PIDD treatment therapies, leading to market growth

 Lack of Adequate Reimbursement and High Treatment Cost Hindering PIDD Market Growth

  • Reimbursement on the national health care system plays a key role in ensuring access to the therapies, but these are not always equally reimbursed in the different countries. For instance, treatment with intravenous or subcutaneous immunoglobulin G (IGG) is covered by the national health system in most countries in Europe. However, it is not consistently available in low- or mid-income regions of the world.
  • Reimbursement policies also vary between different IG therapies and in some countries only one IG product is reimbursed. In some cases, reimbursement is based on the type of PI, meaning that in case of less severe PI, patients have to bear the cost of treatment on their own. Significant disparities in terms of reimbursement are also noticeable according to insurance plan options.
  • Despite the proven effectiveness of intravenous immunoglobulin (IVIG), accessibility to treatment and reimbursement of treatment costs differ by country. IVIG is fully reimbursed by the government: the greatest challenge for treatment is accessibility to a treatment center. Private insurance usually does not provide reimbursement for regular treatment with IVIG for PIDD.
  • Access to laboratory testing is generally limited or, if available, costs to cover testing are difficult. Some screening tests are covered by governmental health programs, but specialized diagnostic tests are typically not reimbursed.
  • IGs are included in the World Health Organization List of Essential Medicines for both adults and children with PI. Several areas are considered by governments and regulatory authorities, which include appropriate supply of IGs on the national healthcare systems to ensure equal access for all individuals and also guarantee (appropriate) reimbursement of therapies.

Rise in Number of Undiagnosed Patients Affecting Revenue Inflow

  • Primary immunodeficiency patients remain undiagnosed or have a substantially delayed diagnosis with adverse results on morbidity and mortality
  • Several studies state that approximately 10 million people suffer from PIDD across the world, whereas it is around 250,000 people in developed countries such as the U.S. However, thousands of children and adults remain undiagnosed or under-diagnosed. This acts as a restraint of the PIDD market not only in developed but also in emerging countries.
  • Health consequences of an undiagnosed disease can include death and severe, life-threatening infections. Moreover, it is a loss of potential revenue for drug manufacturers and diagnostic companies, affecting the PIDD market growth opportunities. Companies should start promotional activities in collaboration with governments and providers (physicians) especially in emerging markets such as Brazil, China, India, Mexico, and Singapore.
  • It is hypothesized that undiagnosed PIDD may burden both the patient with repeated infections and the healthcare system with significant service utilization

 Primary Immunodeficiency Market: Competition Landscape

  • This report profiles major players operating in the global primary immunodeficiency market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global primary immunodeficiency market is moderately fragmented, with the presence of a few large players in the international market and numerous small players in regional markets. The top four to five players hold major share of the global primary immunodeficiency market.
  • Prominent players operating in the global primary immunodeficiency market include 
    • Shire plc
    • CSL Behring
    • Kedrion Biopharma Inc
    • Grifols, S.A
    • Octapharma
    • China Biologic Products Holdings, Inc
    • Biotest AG,
    • Sanquin,
    • LFB SA
  • The report on the global primary immunodeficiency market discusses individual strategies, followed by company profiles of manufacturers of primary immunodeficiency therapeutics. The ‘Competition Landscape’ section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global primary immunodeficiency market.

Primary Immunodeficiency Market - Segmentation

Type

  • Antibody Deficiency
    • Agammaglobulinaemia
    • Common Variable Immune Deficiency
    • Selective IgA Deficiency
    • IgG Subclass Deficiency
    • Others
  • Cellular Deficiency
    • Ataxia Telangiectasia
    • Hyper IgM Syndromes
    • Wiskott-Aldrich Syndrome
    • DiGeorge Syndrome
    • Others
  • Innate Immune
    • Complement Deficiencies
    • Hyper IgE Syndrome
    • Others

End User

  • Immunoglobuline Replacement Therapy
  • Antibiotic Therapy
  • Stem Cell and Gene Therapy
  • Others (Vaccines, Nutritional Supplements, and Others)

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Primary Immunodeficiency Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of primary immunodeficiency market?

Primary immunodeficiency market is expected to attain reach a value of ~US$ 9.9 Bn by the end of 2028

What is the anticipated CAGR of the primary immunodeficiency market in the forecast period?

Primary immunodeficiency market is projected to expand at a CAGR of ~6% from 2020 to 2028​

What are the key driving factors for the growth of the primary immunodeficiency market?

Primary immunodeficiency market is driven by high prevalence of hypertension

Which region is expected to project the highest market share in the global primary immunodeficiency market?

North America accounted for a major share of the global primary immunodeficiency market

Who are the key players in the primary immunodeficiency market?

Key players in the global primary immunodeficiency market include Shire plc, CSL Behring, Kedrion Biopharma Inc, Grifols, S.A, Octapharma

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Primary Immunodeficiency Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Primary Immunodeficiency Market Analysis and Forecast, 2018–2028

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Regulatory Scenario by Region/globally

    5.2. Pipeline Analysis

    5.3. Primary Immunodeficiency Market Clinical Trials

6. Global Primary Immunodeficiency Market Analysis and Forecast, by Type 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Type, 2018–2028

        6.3.1. Antibody Deficiency

            6.3.1.1. Agammaglobulinaemia 

            6.3.1.2. Common Variable Immune Deficiency

            6.3.1.3. Selective IgA Deficiency

            6.3.1.4. IgG Subclass Deficiency

            6.3.1.5. Others 

        6.3.2. Cellular Deficiency

            6.3.2.1. Ataxia Telangiectasia

            6.3.2.2. Hyper IgM Syndromes

            6.3.2.3. Wiskott-Aldrich Syndrome

            6.3.2.4. DiGeorge Syndrome

            6.3.2.5.  Others

        6.3.3. Innate Immune

            6.3.3.1. Complement Deficiencies

            6.3.3.2. Hyper IgE Syndrome

            6.3.3.3. Others

    6.4. Market Attractiveness, by Type 

7. Global Primary Immunodeficiency Market Analysis and Forecast, by Treatment Type 

    7.1. Introduction & Definition

    7.2.  Key Findings / Developments

    7.3. Market Value  Forecast, by Treatment Type, 2018–2028

        7.3.1. Immunoglobuline replacement Therapy

        7.3.2. Antibiotic Therapy

        7.3.3. Stem cell and Gene Therapy

        7.3.4. Others (Vaccines, Nutritional Supplements, and Others)

    7.4. Market Attractiveness, by Treatment Type 

8. Global Primary Immunodeficiency Market Analysis and Forecast, by Region

    8.1.  Key Findings

    8.2. Market Value  Forecast, by Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3.  Asia Pacific 

        8.2.4. Latin America 

        8.2.5.  Middle East & Africa 

    8.3. Market Attractiveness, by Country/Region

9. North America Primary Immunodeficiency Market Analysis and Forecast

    9.1.  Introduction

        9.1.1. Key Findings

    9.2. Market Value  Forecast, by Type, 2018–2028

        9.2.1. Antibody Deficiency

            9.2.1.1. Agammaglobulinaemia 

            9.2.1.2. Common Variable Immune Deficiency

            9.2.1.3. Selective IgA Deficiency

            9.2.1.4. IgG Subclass Deficiency

            9.2.1.5. Others 

        9.2.2. Cellular Deficiency

            9.2.2.1. Ataxia Telangiectasia

            9.2.2.2. Hyper IgM Syndromes

            9.2.2.3. Wiskott-Aldrich Syndrome

            9.2.2.4. DiGeorge Syndrome

            9.2.2.5.  Others

        9.2.3. Innate Immune

            9.2.3.1. Complement Deficiencies

            9.2.3.2. Hyper IgE Syndrome

            9.2.3.3. Others

    9.3. Market Value  Forecast, by Treatment Type, 2018–2028

        9.3.1. Immunoglobuline replacement Therapy

        9.3.2. Antibiotic Therapy

        9.3.3. Stem cell and Gene Therapy

        9.3.4. Others (Vaccines, Nutritional Supplements, and Others)

    9.4. Market Value  Forecast, by Country, 2018–2028

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis 

        9.5.1. By Type 

        9.5.2. By Treatment Type 

        9.5.3. By Country

10. Europe Primary Immunodeficiency Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value  Forecast, by Type, 2018–2028

        10.2.1. Antibody Deficiency

            10.2.1.1. Agammaglobulinaemia 

            10.2.1.2. Common Variable Immune Deficiency

            10.2.1.3. Selective IgA Deficiency

            10.2.1.4. IgG Subclass Deficiency

            10.2.1.5. Others 

        10.2.2. Cellular Deficiency

            10.2.2.1. Ataxia Telangiectasia

            10.2.2.2. Hyper IgM Syndromes

            10.2.2.3. Wiskott-Aldrich Syndrome

            10.2.2.4. DiGeorge Syndrome

            10.2.2.5. Others

        10.2.3. Innate Immune

            10.2.3.1. Complement Deficiencies

            10.2.3.2. Hyper IgE Syndrome

            10.2.3.3. Others

    10.3. Market Value Forecast, by Treatment Type, 2018–2028

        10.3.1. Immunoglobuline Replacement Therapy

        10.3.2. Antibiotic Therapy

        10.3.3. Stem cell and Gene Therapy

        10.3.4. Others (Vaccines, Nutritional Supplements, and Others)

    10.4. Market Value  Forecast, by Country/Sub-region, 2018–2028

        10.4.1.  Germany

        10.4.2. U.K.

        10.4.3.  France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5.  Market Attractiveness Analysis 

        10.5.1. By Type 

        10.5.2. By Treatment Type 

        10.5.3. By Country/Sub-region

11. Asia Pacific Primary Immunodeficiency Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2018–2028

        11.2.1. Antibody Deficiency

            11.2.1.1. Agammaglobulinaemia 

            11.2.1.2. Common Variable Immune Deficiency

            11.2.1.3. Selective IgA Deficiency

            11.2.1.4. IgG Subclass Deficiency

            11.2.1.5. Others 

        11.2.2. Cellular Deficiency

            11.2.2.1. Ataxia Telangiectasia

            11.2.2.2. Hyper IgM Syndromes

            11.2.2.3. Wiskott-Aldrich Syndrome

            11.2.2.4. DiGeorge Syndrome

            11.2.2.5. Others

        11.2.3. Innate Immune

            11.2.3.1. Complement Deficiencies

            11.2.3.2. Hyper IgE Syndrome

            11.2.3.3. Others

    11.3. Market Value Forecast, by Treatment Type, 2018–2028

        11.3.1. Immunoglobuline replacement Therapy

        11.3.2. Antibiotic Therapy

        11.3.3. Stem cell and Gene Therapy

        11.3.4. Others (Vaccines, Nutritional Supplements, and Others)

    11.4. Market Value Forecast, by Country/Sub-region, 2018–2028

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis 

        11.5.1. By Type 

        11.5.2. By Treatment Type 

        11.5.3. By Country/Sub-region

12. Latin America Primary Immunodeficiency Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value  Forecast, by Type, 2018–2028

        12.2.1. Antibody Deficiency

            12.2.1.1. Agammaglobulinaemia 

            12.2.1.2. Common Variable Immune Deficiency

            12.2.1.3. Selective IgA Deficiency

            12.2.1.4. IgG Subclass Deficiency

            12.2.1.5. Others 

        12.2.2. Cellular Deficiency

            12.2.2.1. Ataxia Telangiectasia

            12.2.2.2. Hyper IgM Syndromes

            12.2.2.3. Wiskott-Aldrich Syndrome

            12.2.2.4. DiGeorge Syndrome

            12.2.2.5. Others

        12.2.3. Innate Immune

            12.2.3.1. Complement Deficiencies

            12.2.3.2. Hyper IgE Syndrome

            12.2.3.3. Others

    12.3. Market Value  Forecast, by Treatment Type, 2018–2028

        12.3.1. Immunoglobuline Replacement Therapy

        12.3.2. Antibiotic Therapy

        12.3.3. Stem cell and Gene Therapy

        12.3.4. Others (Vaccines, Nutritional Supplements, and Others)

    12.4. Market Value  Forecast, by Country/Sub-region, 2018–2028

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis 

        12.5.1. By Type 

        12.5.2. By Treatment Type 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Primary Immunodeficiency Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Type, 2018–2028

        13.2.1. Antibody Deficiency

            13.2.1.1. Agammaglobulinaemia 

            13.2.1.2. Common Variable Immune Deficiency

            13.2.1.3. Selective IgA Deficiency

            13.2.1.4. IgG Subclass Deficiency

            13.2.1.5. Others 

        13.2.2. Cellular Deficiency

            13.2.2.1. Ataxia Telangiectasia

            13.2.2.2. Hyper IgM Syndromes

            13.2.2.3. Wiskott-Aldrich Syndrome

            13.2.2.4. DiGeorge Syndrome

            13.2.2.5. Others

        13.2.3. Innate Immune

            13.2.3.1. Complement Deficiencies

            13.2.3.2. Hyper IgE Syndrome

            13.2.3.3. Others

    13.3. Market Value  Forecast, by Treatment Type, 2018–2028

        13.3.1. Immunoglobuline replacement Therapy

        13.3.2. Antibiotic Therapy

        13.3.3. Stem cell and Gene Therapy

        13.3.4. Others (Vaccines, Nutritional Supplements, and Others)

    13.4. Market Value  Forecast, by Country/Sub-region, 2018–2028

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis 

        13.5.1. By Type 

        13.5.2. By Treatment Type 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Market Share Analysis, by Company (2018)

    14.3. Company Profiles

        14.3.1. Shire

            14.3.1.1. Company Overview

            14.3.1.2. Company Financials

            14.3.1.3. Growth Strategies

            14.3.1.4. SWOT Analysis

        14.3.2. CSL Behring 

            14.3.2.1. Company Overview

            14.3.2.2. Company Financials

            14.3.2.3. Growth Strategies

            14.3.2.4. SWOT Analysis

        14.3.3. Kedrion Biopharma Inc. 

            14.3.3.1. Company Overview

            14.3.3.2. Company Financials

            14.3.3.3. Growth Strategies

            14.3.3.4. SWOT Analysis

        14.3.4. Grifols, S.A.

            14.3.4.1. Company Overview

            14.3.4.2. Company Financials

            14.3.4.3. Growth Strategies

            14.3.4.4. SWOT Analysis

        14.3.5. Octapharma

            14.3.5.1. Company Overview

            14.3.5.2. Company Financials

            14.3.5.3. Growth Strategies

            14.3.5.4. SWOT Analysis

        14.3.6. China Biologic Products Holdings, Inc.

            14.3.6.1. Company Overview

            14.3.6.2. Company Financials

            14.3.6.3. Growth Strategies

            14.3.6.4. SWOT Analysis

        14.3.7.  Biotest AG 

            14.3.7.1. Company Overview

            14.3.7.2. Company Financials

            14.3.7.3. Growth Strategies

            14.3.7.4. SWOT Analysis

        14.3.8. Sanquin

            14.3.8.1. Company Overview

            14.3.8.2. Company Financials

            14.3.8.3. Growth Strategies

            14.3.8.4. SWOT Analysis

        14.3.9. LFB SA 

            14.3.9.1. Company Overview

            14.3.9.2. Company Financials

            14.3.9.3. Growth Strategies

            14.3.9.4. SWOT Analysis

        14.3.10. Other Prominent Key Players

List of Tables

Table: 1 Global Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Type, 2018–2028

Table: 2 Global Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028

Table: 3 Global Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028

Table: 4 Global Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028

Table: 5 Global Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2028

Table: 6 Global Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Region, 2018–2028

Table: 7 North America Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Type, 2018–2028

Table: 8 North America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028

Table: 9 North America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028

Table: 10 North America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028

Table: 11 North America Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Treatment Type, 2018–2028

Table: 12 North America Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Country, 2018–2028

Table: 13 Europe Primary Immunodeficiency Market Revenue (US$ Mn) Forecast, by Type, 2018–2028

Table: 14 Europe Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028

Table: 15 Europe Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028

Table: 16 Europe Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028

Table: 17 Europe Primary Immunodeficiency Market Revenue (US$ Mn) Forecast, by Treatment Type, 2018–2028

Table: 18 Europe Primary Immunodeficiency Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

Table: 19 Asia Pacific Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Type, 2018–2028

Table: 20 Asia Pacific Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028

Table: 21 Asia Pacific Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028

Table: 22 Asia Pacific Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028

Table: 23 Asia Pacific Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Treatment Type, 2018–2028

Table: 24 Asia Pacific Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

Table: 25 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Type, 2018–2028

Table: 26 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028

Table: 27 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028

Table: 28 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028

Table: 29 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2028

Table: 30 Latin America Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

Table: 31 Middle East & Africa Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Type, 2018–2028

Table: 32 Middle East & Africa Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Antibody Deficiency, 2018–2028

Table: 33 Middle East & Africa Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Cellular Deficiency, 2018–2028

Table: 34 Middle East & Africa Primary Immunodeficiency Market Size (US$ Mn) Forecast, by Innate Immune, 2018–2028

Table: 35 Middle East & Africa Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Treatment Type, 2018–2028

Table: 36 Middle East & Africa Primary Immunodeficiency Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

List of Figures

Figure: 1 Market Value, by Type (US$ Mn), 2018

Figure: 2 Market Share, Top Trends by Type (2018)

Figure: 3 Market Share by Region, 2018

Figure: 4 Market Share Analysis, by Region

Figure: 5 Porter’s Five Forces Analysis 

Figure: 6 Global Primary Immunodeficiency Market Value (US$ Mn) and Forecast, 2019–2028

Figure: 7 Global Market Value Share, by Type (2018)

Figure: 8 Global Market Value Share, by Treatment Type (2018)

Figure: 9 Global Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028

Figure: 10 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antibody Deficiency, 2018–2028

Figure: 11 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cellular Deficiency, 2018–2028

Figure: 12 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Innate Immune, 2018–2028

Figure: 13 Global Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019–2028

Figure: 14 Global Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028

Figure: 15 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunoglobuline Replacement Therapy, 2018–2028

Figure: 16 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antibiotic Therapy, 2018–2028

Figure: 17 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Stem cell and Gene Therapy, 2018–2028

Figure: 18 Global Primary Immunodeficiency Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others (Vaccines, Nutritional Supplements and others), 2018–2028

Figure: 19 Global Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019–2028

Figure: 20 Global Primary Immunodeficiency Market Value Share Analysis, by Region, 2018 and 2028

Figure: 21 Global Primary Immunodeficiency Market Attractiveness Analysis, by Region, 2019–2028

Figure: 22 North America Primary Immunodeficiency Market Value (US$ Mn) Forecast, 2018–2028

Figure: 23 North America Primary Immunodeficiency Market Attractiveness Analysis, by Country, 2019–2028

Figure: 24 North America Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028

Figure: 25 North America Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028

Figure: 26 North America Primary Immunodeficiency Market Value Share Analysis, by Country, 2018 and 2028

Figure: 27 North America Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019-2028

Figure: 28 North America Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019-2028

Figure: 29 Europe Primary Immunodeficiency Market Value (US$ Mn) Forecast, 2018–2028

Figure: 30 Europe Primary Immunodeficiency Market Attractiveness Analysis, by Country/Sub-region, 2019–2028

Figure: 31 Europe Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028

Figure: 32 Europe Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028

Figure: 33 Europe Primary Immunodeficiency Market Value Share Analysis, by Country/Sub-region, 2018 and 2028

Figure: 34 Europe Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019-2028

Figure: 35 Europe Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019-2028

Figure: 36 Asia Pacific Primary Immunodeficiency Market Value (US$ Mn) Forecast, 2018–2028

Figure: 37 Asia Pacific Primary Immunodeficiency Market Attractiveness Analysis, by Country/Sub-region, 2019–2028

Figure: 38 Asia Pacific Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028

Figure: 39 Asia Pacific Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028

Figure: 40 Asia Pacific Primary Immunodeficiency Market Value Share Analysis, by Country/Sub-region, 2018 and 2028

Figure: 41 Asia Pacific Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019-2028

Figure: 42 Asia Pacific Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019-2028

Figure: 43 Latin America Primary Immunodeficiency Market Value (US$ Mn) Forecast, 2018–2028

Figure: 44 Latin America Primary Immunodeficiency Market Attractiveness Analysis, by Country/Sub-region, 2019–2028

Figure: 45 Latin America Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028

Figure: 46 Latin America Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028

Figure: 47 Latin America Primary Immunodeficiency Market Value Share Analysis, by Country/Sub-region, 2018 and 2028

Figure: 48 Latin America Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019-2028

Figure: 49 Latin America Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019-2028

Figure: 50 Middle East & Africa Primary Immunodeficiency Market Value (US$ Mn) Forecast, 2018–2028

Figure: 51 Middle East & Africa Primary Immunodeficiency Market Attractiveness Analysis, by Country/Sub-region, 2019–2028

Figure: 52 Middle East & Africa Primary Immunodeficiency Market Value Share Analysis, by Type, 2018 and 2028

Figure: 53 Middle East & Africa Primary Immunodeficiency Market Value Share Analysis, by Treatment Type, 2018 and 2028

Figure: 54 Middle East & Africa Primary Immunodeficiency Market Value Share Analysis, by Country/Sub-region, 2018 and 2028

Figure: 55 Middle East & Africa Primary Immunodeficiency Market Attractiveness Analysis, by Type, 2019-2028

Figure: 56 Middle East & Africa Primary Immunodeficiency Market Attractiveness Analysis, by Treatment Type, 2019-2028

Figure: 57 Shire PLC Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017

Figure: 58 Shire PLC Research & Development Expenses (2017)

Figure: 59 Shire PLC Breakdown of Net Sales (% Share), by Business Segment (2017)

Figure: 60 Shire PLC Breakdown of Net Sales (% Share), by Region (2017)

Figure: 61 CSL Behring Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018

Figure: 62 CSL Behring Research and Development Expenses, 2014-2018

Figure: 63 CSL Behring Breakdown of Net Sales (% Share), by Region (2017-2018)

Figure: 64  Kedrion Biopharma Inc Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2017

Figure: 65  Kedrion Biopharma Inc Research and Development Expenses, 2013-2017

Figure: 66  Kedrion Biopharma Inc Breakdown of Net Sales (% Share), by Business Segment (2017)

Figure: 67  Kedrion Biopharma Inc Breakdown of Net Sales (% Share), by Region (2017)

Figure: 68 Grifols, S. A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2017

Figure: 69  Grifols, S. A. Research and Development Expenses, 2013-2017

Figure: 70 Grifols, S. A. Breakdown of Net Sales (% Share), by Business Segment (2017)

Figure: 71 Grifols, S. A. Breakdown of Net Sales (% Share), by Region (2017)

Figure: 72 Octapharma Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2017

Figure: 73 Octapharma Research and Development Expenses, 2013-2017

Figure: 74 China Biologic Products Holdings, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017

Figure: 75 China Biologic Products Holdings, Inc. Breakdown of Net Sales, by Business Segment, 2017

Figure: 76 China Biologic Products Holdings, Inc. Research & Development Cost, 2015–2017 (US$ Mn)

Figure: 77 Biotest AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017

Figure: 78 Biotest AG Breakdown of Net Sales, by Country, 2017

Figure: 79 Biotest AG Breakdown of Net Sales, by business segment, 2017(US$ Mn)

Figure: 80 Sanquin Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017

Figure: 81 Sanquin Research & Development Expenses 2016 and 2017

Figure: 82 Sanquin Breakdown of Net Sales (% Share), by Business Segment (2017)

Figure: 83 Sanquin Breakdown of Net Sales (% Share), by Region (2017)

Figure: 84 LFB S.A. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016

Figure: 85 LFB S.A. Breakdown of Net Sales, by Region, 2016

Figure: 86 LFB S.A. Breakdown of Net Sales, by Business Segment, 2016

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

873

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved